Bayer AG

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Bayer Aktiengesellschaft (BAYRY) is a Top Value Stock for the Long-Term

PITTSBURGH--( BUSINESS WIRE )--As international leaders in the field of Imaging gather for the 2022 Radiological Society of North America (RSNA) Annual Meeting, Bayer Radiology, a leader in diagnostic imaging, will showcase its portfolio of products and solutions intended to address today's most pressing issues facing the field of Radiology. In addition, Bayer will present new scientific data on an investigational contrast agent. The 2022 RSNA will take place from November 27 to December 1 in Chicago.

2022 Radiological Society of North America (RSNA) Annual Meeting: Bayer to showcase product offerings and announces broadened AI offering in Radiology

BASF SE

Ford Motor Company

Barrick Gold

Orange

Stellantis N.V. 

Vale S.A.

Cheap blue-chip stocks under $15 can be rare finds. Typically since financially sound firms with recognizable names have histories of strong performance and often include dividends, their prices tend to be higher.

7 Cheap Blue-Chip Stocks Under $15 to Buy Now

DAVIS, Calif.--( BUSINESS WIRE )--OpenFold, a non-profit artificial intelligence (AI) research consortium whose goal is to develop free and open source software tools for biology and drug discovery, today announced the addition of four new industry members: Bayer, Dassault Systèmes, CHARM Therapeutics, and BaseCamp Research Ltd.

OpenFold AI Research Consortium Welcomes 4 New Members: Bayer, Dassault, CHARM Therapeutics and BaseCamp Research

Novo Nordisk

BAYRY vs. NVO: Which Stock Is the Better Value Option?

Bayer (BAYRY) gets positive recommendation from the CHMP for label extension of ophthalmology drug Eylea for the treatment of preterm infants with retinopathy of prematurity.

Bayer (BAYRY) Eylea Label Extension Gets CHMP Positive Opinion

Bayer AG (OTCPK:BAYZF) Q3 2022 Earnings Conference Call November 8, 2022 8:00 AM ET Company Participants Oliver Maier - Head, IR Werner Baumann - Chairman, CEO & Chief Sustainability Officer Wolfgang Nickl - CFO Heiko Schipper - President, Consumer Health Division Rodrigo Santos - President, Crop Science Division Stefan Oelrich - Head, Pharmaceuticals Division Conference Call Participants Michael Leuchten - UBS Richard Vosser - JPMorgan Chase & Co. Peter Verdult - Citi Vincent Andrews - Morgan Stanley Sachin Jain - Bank of America Merrill Lynch Laurent Favre - Exane BNP Paribas Dominic Lunn - Crédit Suisse Keyur Parekh - Goldman Sachs James Quigley - Morgan Stanley Falko Friedrichs - Deutsche Bank Operator Good day, and thank you for standing by. Welcome to Bayer's Investor and Analyst Conference Call on the Third Quarter 2022 Results.

Bayer AG (BAYZF) Q3 2022 Earnings Call Transcript

Bayer's (BAYRY) earnings fall shy of estimates in the third quarter of 2022 while revenues beat the same.

Bayer's (BAYRY) Q3 Earnings Miss Estimates, Revenues Top

Bayer, together with the Bill & Melinda Gates Foundation, are jointly funding pre-clinical research in non-hormonal contraception

Bayer Signs Grant Agreement to Advance Research in Non-Hormonal Contraception

Bayer AG on Tuesday backed its 2022 financial objectives after third-quarter sales beat expectations and it reported earnings growth in all its segments.

Bayer backs outlook after forecast beating sales of €11.28 billion

Agriculture and pharmaceuticals company Bayer on Tuesday reported better-than-expected quarterly earnings as surging demand for its herbicides made up for a decline in sales of its stroke prevention pill Xarelto.

Bayer beats Q3 profit forecast on strong herbicide sales

OASIS- 4 plans to investigate elinzanetant as a non-hormonal treatment for vasomotor symptoms caused by endocrine therapy in breast cancer patients

Outside the US Bayer Extends Development Program for Investigational Product Elinzanetant With Phase III Study in Breast Cancer Patients With Vasomotor Symptoms Caused by Endocrine Therapy

Bestinfond (Trades, Portfolio), a fund that is part of Spain-based Bestinver, disclosed in a recent regulatory filing that its top trades during the third quarter included new holdings in Bayer AG ( XTER:BAYN , Financial) and Banco Bilbao Vizcaya Argentaria SA ( XMAD:BBVA , Financial), the closure of its positions in easyJet PLC ( LSE:EZJ , Financial) and Repsol SA (XMAD:REP) and a reduction to its holding in Intesa Sanpaolo ( MIL:ISP , Financial).

Bestinfond Opens Stake in Bayer, Discards easyJet in 3rd Quarter

Further post-hoc analysis from FIDELITY, a prespecified, exploratory pooled analysis of FIDELIO-DKD and FIGARO-DKD Phase III studies, investigates the efficacy and safety of KERENDIA in patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) who have sustained an acute change in estimated glomerular filtration rate (eGFR) upon drug initiation1

Bayer to Highlight Additional Analyses From Comprehensive KERENDIA® (finerenone) Clinical Trial Program at the American Society of Nephrology's 2022 Kidney Week

Bayer Aktiengesellschaft (BAYRY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Bayer Aktiengesellschaft (BAYRY) Upgraded to Buy: Here's Why

BAYRY or NVO: Which Is the Better Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Bayer (BAYRY) a Great Value Stock Right Now?

AP Moller - Maersk A/S

GlaxoSmithKline

Himax Tech

Ituran Location & Control

Bank of N.T. Butterfield & Son

Schneider Electric SE

Sibanye Stillwater

Telefonica Brasil

Vodafone Group

Subscribers to my Dividend Dogcatcher Marketplace (behind the SA paywall) know my Viital portfolio (#VII) stocks are “selected based-on gains, yield, momentum, price-upside, dividend-history, analyst-interest, special-market qualities, and dividend-safety.”. By yield, HIMX topped-all Viital eX-US candidates. Top-ten Yields from NTB, EMBVF, BCE, SBSW, GSK, VOD, VALE, CRARF, AMKBY, and HIMX averaged 9.94%.

15 Top October Ex-U.S. Dividend Dogs, Which One To Buy?

Bayer's KERENDIA® (finerenone), a first-in-class, non-steroidal mineralocorticoid receptor antagonist (ns-MRA), was recommended as part of a comprehensive treatment strategy for patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) in a newly published update to the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease and in a consensus report jointly issued by KDIGO and the American Diabetes Association (ADA).1-3

Bayer's KERENDIA® (finerenone) Recommended as Part of Comprehensive Treatment Strategy for Chronic Kidney Disease Associated With Type 2 Diabetes in Newly Published Clinical Recommendations

SEATTLE--(BUSINESS WIRE)-- #carbonremoval--Nori today announced a collaboration with Bayer's ForGround platform to scale Nori's unique carbon removal offset marketplace.

Nori Partners With Bayer's ForGround Platform to Scale Its Carbon Marketplace Through Verified Carbon Removals

European stocks - including Bayer - we punished in the last few months, and the potential energy crisis could be a reason. But Bayer is reporting solid quarterly results and could increase its fiscal 2022 guidance.

Bayer: Significant Upside Despite A Challenging Environment

WHIPPANY, N.J.--(BUSINESS WIRE)--The American Association of Clinical Endocrinology (AACE) issued an update to its Developing a Diabetes Mellitus Comprehensive Care Plan guideline, which included a grade A recommendation* for Bayer's KERENDIA® (finerenone), a first-in-class non-steroidal mineralocorticoid receptor antagonist (ns-MRA), for the management of patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).1 KERENDIA was approved by the FDA in July 2021 to reduce t

Bayer's KERENDIA® (finerenone) Receives Grade A Recommendation as Treatment Option for Patients With Chronic Kidney Disease Associated With Type 2 Diabetes in Latest Guideline Update From American Association of Clinical Endocrinology

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, one of the country's leading life-sciences companies, announced today that William (Bill) Dodero, its current Vice President and Global Head of Litigation, will become the company's new U.S. General Counsel and Senior Vice President, as well as a member of the U.S. Country Leadership Team. Dodero succeeds Scott Partridge who decided to depart Bayer at the end of the year after 16 years at Monsanto and Bayer to focus on dispute resolution representation an

Bayer Names William Dodero New U.S. General Counsel Beginning January 2023

LEVERKUSEN, Germany--(BUSINESS WIRE)--Bayer has completed the sale of its Environmental Science Professional business to the international private equity firm Cinven, after the two companies had entered into a corresponding agreement in March. The conditions for closing the transaction – including the receipt of regulatory approval – have now been met. The purchase price for the business, which generated sales of approximately 600 million euros in 2021, amounts to 2.6 billion U.S. dollars. “We

Bayer Completes Sale of Its Environmental Science Professional Business to Cinven

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Fund, the philanthropic arm of Bayer in the U.S., is proud to announce today that it has provided a total of $8.2M in grant funding, spanning across 2,085 organizations, in the first half of 2022. As part of Bayer's broader vision of ensuring Health for All, Hunger for None, each Bayer Fund grant goes towards programs that help solve some of the country's – and world's – biggest challenges, including access to food and nutrition, STEM education and health

Bayer Fund Announces $8.2M in Donations to U.S. Nonprofit Organizations During First Half of 2022

News for Bayer AG Stock (BAYRY)